Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KZR
stocks logo

KZR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.310
-56.33%
--
--
-1.270
-36.5%
--
--
-1.255
-32.89%
Estimates Revision
The market is revising No Change the revenue expectations for Kezar Life Sciences, Inc. (KZR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 53.56%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+53.56%
In Past 3 Month
Wall Street analysts forecast KZR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZR is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast KZR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZR is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
3 Hold
0 Sell
Hold
Current: 6.250
sliders
Low
5.00
Averages
6.00
High
7.00
Current: 6.250
sliders
Low
5.00
Averages
6.00
High
7.00
Jefferies
Maury Raycroft
Buy -> Hold
downgrade
$18 -> $7
2025-10-17
Reason
Jefferies
Maury Raycroft
Price Target
$18 -> $7
2025-10-17
downgrade
Buy -> Hold
Reason
Jefferies analyst Maury Raycroft downgraded Kezar Life Sciences to Hold from Buy with a price target of $7, down from $18. The company announced it could not align with the FDA on a registrational path for zetomipzomib in autoimmune hepatitis, leading to a formal process to explore strategic alternatives, the analyst tells investors in a research note. The firm lowered the probability of sucess of zetomipzomib to 10% from 25% and downgraded the shares.
William Blair
Matthew Phipps
Outperform -> Market Perform
downgrade
2025-10-17
Reason
William Blair
Matthew Phipps
Price Target
2025-10-17
downgrade
Outperform -> Market Perform
Reason
William Blair analyst Matthew Phipps downgraded Kezar Life Sciences to Market Perform from Outperform without a price target. The company announced it has been unable to align with the FDA on a registrational trial for zetomipzomib in autoimmune hepatitis and is initiating a process to explore strategic alternatives, the analyst tells investors in a research note. The firm is surprised to see the FDA refusing to host a Type C meeting. Considering Kezar's current cash balance and liabilities, Blair believes a potential acquisition in the $6 to $7 per share range could be feasible.
Wells Fargo
Equal Weight
downgrade
$7 -> $5
2025-10-17
Reason
Wells Fargo
Price Target
$7 -> $5
2025-10-17
downgrade
Equal Weight
Reason
Wells Fargo lowered the firm's price target on Kezar Life Sciences to $5 from $7 and keeps an Equal Weight rating on the shares. The firm notes management reported it was unable to align with the FDA on a Phase 3 for zetomipzomib in autoimmune hepatitis, effectively killing the program. Wells thinks there could be upside if they return cash to shareholders or in a reverse merger scenario and why shares are trading up +45% post market.
Wells Fargo
Derek Archila
Hold
Maintains
$11 → $9
2024-12-19
Reason
Wells Fargo
Derek Archila
Price Target
$11 → $9
2024-12-19
Maintains
Hold
Reason
Wells Fargo analyst Derek Archila lowered the firm's price target on Kezar Life Sciences to $9 from $11 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR).
See All Ratings

Valuation Metrics

The current forward P/E ratio for Kezar Life Sciences Inc (KZR.O) is -1.23, compared to its 5-year average forward P/E of -3.80. For a more detailed relative valuation and DCF analysis to assess Kezar Life Sciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.80
Current PE
-1.23
Overvalued PE
-0.03
Undervalued PE
-7.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
8.26
Current PS
0.00
Overvalued PS
24.08
Undervalued PS
-7.55
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

KZR News & Events

Events Timeline

(ET)
2025-12-02
09:40:00
Kazia Therapeutics Trading Halted Due to Volatility Trading Pause
select
2025-11-12 (ET)
2025-11-12
16:04:40
Kezar Life Sciences Announces Q3 EPS of $1.53, Below Consensus Estimate of $1.96
select
2025-10-16 (ET)
2025-10-16
16:07:19
Kezar Life Sciences to consider strategic options
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
10-18Benzinga
Jefferies Lowers Kezar Life Sciences Rating to Hold and Reduces Price Target to $7

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.

  • Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

[object Object]
Preview
9.0
10-18Benzinga
Kezar Initiates Strategic Review Following FDA Setback on Liver Drug Development

  • Regulatory Challenges: Kezar Life Sciences is facing difficulties in aligning with the FDA regarding a clinical trial for zetomipzomib aimed at treating autoimmune hepatitis, leading to the cancellation of a scheduled Type C meeting and a requirement for additional studies that could delay future trials by approximately two years.

  • Strategic Review and Restructuring: The company has initiated a strategic review process with the help of TD Cowen and plans to implement a restructuring plan that includes workforce reductions and cost-containment measures, while also experiencing a significant increase in stock price despite recent challenges.

[object Object]
Preview
4.0
09-17NASDAQ.COM
Everything You Should Know About the Upgrade to Buy for Kezar Life Sciences (KZR)

  • Kezar Life Sciences Upgrade: Kezar Life Sciences, Inc. (KZR) has received a Zacks Rank #2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which could lead to favorable stock price movements.

  • Importance of Earnings Estimates: The Zacks rating system emphasizes the correlation between earnings estimate revisions and stock price trends, suggesting that tracking these revisions can be beneficial for investors seeking to make informed decisions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Kezar Life Sciences Inc (KZR) stock price today?

The current price of KZR is 6.25 USD — it has increased 0.16 % in the last trading day.

arrow icon

What is Kezar Life Sciences Inc (KZR)'s business?

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The Company is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.

arrow icon

What is the price predicton of KZR Stock?

Wall Street analysts forecast KZR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZR is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Kezar Life Sciences Inc (KZR)'s revenue for the last quarter?

Kezar Life Sciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Kezar Life Sciences Inc (KZR)'s earnings per share (EPS) for the last quarter?

Kezar Life Sciences Inc. EPS for the last quarter amounts to -1.53 USD, decreased -94.50 % YoY.

arrow icon

What changes have occurred in the market's expectations for Kezar Life Sciences Inc (KZR)'s fundamentals?

The market is revising No Change the revenue expectations for Kezar Life Sciences, Inc. (KZR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 53.56%.
arrow icon

How many employees does Kezar Life Sciences Inc (KZR). have?

Kezar Life Sciences Inc (KZR) has 55 emplpoyees as of December 05 2025.

arrow icon

What is Kezar Life Sciences Inc (KZR) market cap?

Today KZR has the market capitalization of 45.70M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free